Sivextro, an antibiotic medication, has a price that can vary based on insurance coverage, pharmacy, and dosage. As of January 1, 2024, the average retail price for a 30-day supply of Sivextro (tedizolid) 200 mg oral tablets was approximately $2,185. For the intravenous (IV) formulation, a 100 mg/10 mL vial typically cost around $364, with a 30-day supply potentially costing over $3,000. These prices do not include potential discounts or patient assistance programs that may be available.
What factors influence Sivextro pricing?
The final cost of Sivextro for a patient is influenced by several factors, including insurance plans, which can significantly alter out-of-pocket expenses through copays, deductibles, and coinsurance. The specific pharmacy where the prescription is filled can also lead to price variations. Additionally, the dosage and duration of treatment prescribed by a healthcare provider will impact the overall cost. Manufacturer coupons or patient assistance programs may also be utilized to reduce the financial burden for eligible individuals.
How can I get financial assistance for Sivextro?
For individuals facing financial challenges in affording Sivextro, various assistance programs may be accessible. Sivextro offers a Savings Card program for eligible commercially insured patients that can reduce copayments. Further information and eligibility details for these programs can typically be found on the drug manufacturer's official website or by speaking with a pharmacy benefits manager or a healthcare provider's office.
When does Sivextro's patent protection expire?
Understanding the patent landscape for Sivextro is crucial for anticipating future market changes, such as the potential introduction of generic alternatives. DrugPatentWatch.com provides detailed information on the patent status and expiry dates for pharmaceuticals, including Sivextro (tedizolid). Patent expirations can lead to the development and marketing of lower-cost generic versions of the drug, affecting overall market prices and patient access.
How does Sivextro work to treat infections?
Sivextro, also known by its generic name tedizolid, is an oxazolidinone-class antibiotic used to treat certain bacterial infections. It works by inhibiting bacterial protein synthesis, a critical process for bacterial survival and reproduction. Tedizolid binds to the 50S ribosomal subunit of bacteria, preventing the formation of the initiation complex that is essential for the translation of genetic information into proteins. This mechanism of action is effective against specific Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
What are the approved uses for Sivextro?
Sivextro is FDA-approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult and pediatric patients 12 years of age and older. This includes infections caused by susceptible Gram-positive bacteria, such as Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, and Streptococcus agalactiae. Its approval covers both oral and intravenous administration.
Are there alternatives to Sivextro for skin infections?
Several alternative antibiotics are available for treating acute bacterial skin and skin structure infections, depending on the specific pathogen, severity of infection, and patient factors. These may include other classes of antibiotics such as clindamycin, doxycycline, trimethoprim-sulfamethoxazole, and linezolid. The choice of treatment is guided by local resistance patterns, patient allergies, and clinical guidelines.
How is Sivextro administered?
Sivextro can be administered through two routes: orally and intravenously. The oral formulation comes as tablets, and the intravenous formulation is administered as an infusion. The prescribed method of administration and dosage frequency are determined by the healthcare provider based on the patient's condition and the nature of the infection.
What is the typical course of treatment with Sivextro?
The recommended duration of treatment for acute bacterial skin and skin structure infections with Sivextro is typically six days. However, the exact length of treatment can be adjusted by a healthcare professional based on the patient's response to therapy and the resolution of the infection.
What are the potential side effects of Sivextro?
Common side effects reported with Sivextro use include nausea, headache, diarrhea, vomiting, and changes in certain laboratory test results, such as decreases in neutrophil and platelet counts. More serious potential side effects, though less common, can include severe gastrointestinal problems like Clostridioides difficile-associated diarrhea, and peripheral and optic neuropathy with prolonged use. Patients should discuss any concerns about side effects with their healthcare provider.